8,500 Shares in Illumina, Inc. $ILMN Purchased by Monetta Financial Services Inc.

Monetta Financial Services Inc. acquired a new position in shares of Illumina, Inc. (NASDAQ:ILMN) in the 3rd quarter, according to its most recent filing with the SEC. The fund acquired 8,500 shares of the life sciences company’s stock, valued at approximately $807,000.

Other hedge funds have also made changes to their positions in the company. Next Capital Management LLC acquired a new stake in shares of Illumina in the second quarter valued at about $341,000. Generali Asset Management SPA SGR boosted its position in Illumina by 51.6% during the third quarter. Generali Asset Management SPA SGR now owns 22,249 shares of the life sciences company’s stock worth $2,113,000 after acquiring an additional 7,574 shares during the last quarter. Andra AP fonden grew its stake in Illumina by 426.3% during the 2nd quarter. Andra AP fonden now owns 102,491 shares of the life sciences company’s stock valued at $9,779,000 after acquiring an additional 83,017 shares in the last quarter. Aaron Wealth Advisors LLC raised its holdings in Illumina by 342.6% in the 3rd quarter. Aaron Wealth Advisors LLC now owns 10,476 shares of the life sciences company’s stock valued at $995,000 after acquiring an additional 8,109 shares during the last quarter. Finally, Douglas Lane & Associates LLC raised its holdings in Illumina by 6.6% in the 3rd quarter. Douglas Lane & Associates LLC now owns 307,609 shares of the life sciences company’s stock valued at $29,214,000 after acquiring an additional 18,914 shares during the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

Insider Buying and Selling

In other Illumina news, SVP Patricia Leckman sold 2,370 shares of Illumina stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $116.18, for a total value of $275,346.60. Following the transaction, the senior vice president directly owned 16,321 shares in the company, valued at approximately $1,896,173.78. This trade represents a 12.68% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Scott M. Davies sold 323 shares of the business’s stock in a transaction that occurred on Friday, December 12th. The shares were sold at an average price of $136.09, for a total value of $43,957.07. Following the completion of the transaction, the insider directly owned 17,887 shares in the company, valued at approximately $2,434,241.83. The trade was a 1.77% decrease in their position. The disclosure for this sale is available in the SEC filing. 0.17% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

ILMN has been the topic of several recent research reports. Stifel Nicolaus boosted their target price on Illumina from $135.00 to $155.00 and gave the stock a “buy” rating in a report on Tuesday, January 20th. Guggenheim upped their price objective on Illumina from $144.00 to $170.00 and gave the company a “buy” rating in a report on Monday, January 26th. Canaccord Genuity Group increased their price target on Illumina from $130.00 to $150.00 and gave the stock a “hold” rating in a report on Monday, January 26th. Evercore set a $150.00 price objective on Illumina in a research report on Friday, February 6th. Finally, TD Cowen reaffirmed a “hold” rating on shares of Illumina in a research report on Wednesday, January 7th. Six analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, Illumina has a consensus rating of “Hold” and an average price target of $127.94.

Illumina Stock Up 2.4%

Illumina stock opened at $120.54 on Tuesday. Illumina, Inc. has a 1-year low of $68.70 and a 1-year high of $155.53. The stock has a market cap of $18.43 billion, a PE ratio of 22.12, a P/E/G ratio of 2.25 and a beta of 1.45. The company has a debt-to-equity ratio of 0.55, a current ratio of 2.08 and a quick ratio of 1.72. The stock’s fifty day moving average is $135.52 and its two-hundred day moving average is $117.54.

Illumina (NASDAQ:ILMN) last announced its earnings results on Thursday, February 5th. The life sciences company reported $1.35 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.26 by $0.09. Illumina had a net margin of 19.57% and a return on equity of 31.04%. The business had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.10 billion. During the same period last year, the firm posted $0.95 earnings per share. The company’s revenue for the quarter was up 5.0% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. On average, sell-side analysts expect that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Illumina Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.